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A general semi-parametric approach to the
analysis of genetic association studies in
population-based designs
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Abstract
Background: For genetic association studies in designs of unrelated individuals, current statistical methodology
typically models the phenotype of interest as a function of the genotype and assumes a known statistical model for
the phenotype. In the analysis of complex phenotypes, especially in the presence of ascertainment conditions, the
speciﬁcation of such model assumptions is not straight-forward and is error-prone, potentially causing misleading
results.
Results: In this paper, we propose an alternative approach that treats the genotype as the random variable and
conditions upon the phenotype. Thereby, the validity of the approach does not depend on the correctness of
assumptions about the phenotypic model. Misspeciﬁcation of the phenotypic model may lead to reduced statistical
power. Theoretical derivations and simulation studies demonstrate both the validity and the advantages of the
approach over existing methodology. In the COPDGene study (a GWAS for Chronic Obstructive Pulmonary Disease
(COPD)), we apply the approach to a secondary, quantitative phenotype, the Fagerstrom nicotine dependence score,
that is correlated with COPD aﬀection status. The software package that implements this method is available.
Conclusions: The ﬂexibility of this approach enables the straight-forward application to quantitative phenotypes and
binary traits in ascertained and unascertained samples. In addition to its robustness features, our method provides the
platform for the construction of complex statistical models for longitudinal data, multivariate data, multi-marker tests,
rare-variant analysis, and others.
Keywords: Genetic associations studies, Secondary phenotypes, Case-control, Ascertainment, Semi-parametric
Background
In genetic association studies, individuals are often
recruited based on case-control ascertainment conditions
of the primary phenotype [1]. For the analysis of sec-
ondary phenotypes, this recruitment-scheme can become
problematic.Ifthesecondaryphenotypeiscorrelatedwith
the primary phenotype in a case-control study, the distri-
bution of the secondary phenotype can be fundamentally
diﬀerent from the general population. For example, in a
genetic association study of COPD in which all cases have
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COPD and control subjects have normal pulmonary func-
tion, the distribution of quantitative lung phenotypes can
deviate substantially from their distribution in the gen-
eral population. For samples that are ascertained in this
fashion, standard statistical methods may lead to mis-
leading results or may lack statistical power to identify
true genotype phenotype associations. There are several
methods to accurately estimate the odds ratio of genetic
variants for binary secondary phenotypes associated with
case-control status [2-10], but these methods cannot eas-
ily accommodate continuous secondary phenotypes. For
the special case that the secondary phenotype is normally
distributed or binary, Lin & Zeng (2009) proposed an
adjusted score test that incorporates genetic associations
with aﬀection status into the test statistic [11].
© 2013 Lutz et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.Lutz etal. BMCGenetics 2013, 14:13 Page 2 of 8
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We present a more general approach that does not
require any distribution assumptions for the secondary
phenotype. We refer to the approach as the non-
parametric population-based association test (NPBAT).
T h ea p p r o a c hh a saf o r ms i m i l a rt ot h eF a m i l yB a s e d
Association Test (FBAT), a non-parametric test statis-
tic that is frequently used in the family based setting
[12-15]. The ﬂexibility of our approach allows us to con-
struct a genetic association test for standard and complex
phenotypes that is non-parametric with respect to the
phenotype. The class of tests is very general. It includes
moststandardassociationtestsandcanbeappliedtomul-
tivariate traits and phenotypes, multiple genetic markers,
and case- control studies where phenotypic information is
available for the cases but correlated with the case-control
status [16-18].
The general concept of the proposedassociation-testing
framework is to condition on the phenotype of interest
and treat only the genetic data as random [12,13,15]. By
assuming that the phenotype data is deterministic, the
validity of the approach does not depend on the cor-
rectness of the phenotypic assumptions. Nevertheless, the
power of the approach can be increased by incorporat-
ing a plausible model for the phenotype into the test
statistic. Based on theoretical considerations and on sim-
ulation studies, we show that the new approach is robust
againstmisspeciﬁcationofphenotypeassumptions.Atthe
same time, this approach achieves the same power level
as standard genetic association tests for population-based
designs when the phenotype of interest has a normal
distribution or is dichotomous. For studies where a quan-
titative trait is correlated with case-control status, our
simulation studies examine the power and signiﬁcance
levels for the proposed approach, which does not require
any adjustment for the ascertainment conditions.
We illustrate the practical advantages of NPBAT by
an application to the COPDGene study. The COPDGene
study is a case-control study of the genetics of COPD
in current or former smokers with at least 10 pack-years
of smoking history [19]. We test the genetic associa-
tion of single nucleotide polymorphisms (SNPs) in the
CHRNA 3/5 region and the Fagerstrom Nicotine Depen-
dence score (FNDS). FNDS is a validated instrument of
nicotine dependence in current smokers and was mea-
sured in the current smokers, but not former smokers in
the COPDGene study. NPBAT, which uses the genotype
data in both current and former smokers, is compared to
the published genetic association of SNPs in the CHRNA
3/5 region and FNDS that was performed in current
smokers only [20].
Methods
In a genetic association study, n unrelated study subjects
have been recruited based on a predeﬁned ascertainment
condition. Let Xi denote the genotype of the individual
i. The speciﬁc value of Xi will depend upon the genetic
model under consideration. For instance, for an additive
model, Xi = 0,1,2 for 0,1,2 disease alleles, respectively.
Xi may also be a vector in order to test several alleles
simultaneously. Let Ti denote the numerical trait infor-
mation for individual i. For example, Ti could equal one
for aﬀected individuals and Ti could equal zero for unaf-
fected individuals. Diﬀerent coding functions are applied
depending on the phenotype of interest. For binary and
continuous traits, we will discuss eﬃcient coding schemes
below. First, we deﬁne a general class of test statistics as
S =
n 
i=1
(Xi − Ex)Ti (1)
Note that E(S) = 0 under the null hypothesis of no
association between the genotype X and the phenotype Y.
Constructing a conditional score test in which the geno-
type Xi is the dependent variable and we condition upon
the numerical trait information Ti, the NPBAT statistic
has the following form:
StatNPBAT =
S − E[S]
√
var(S)
=
n 
i=1
(Xi − Ex)Ti
 n 
i=1
T2
i
n
i=1(Xi−Ex)2
n−1

(2)
where Ex denotes the expectation of the marker score/
genotype X under the null-hypothesis of no genetic asso-
ciation between the phenotype. The marker locus. Ex can
be estimated based on the sample mean of the genotypes.
The asymptotic distribution of the NPBAT statistic under
the null-hypothesis depends on the estimation of Ex and
on the speciﬁcation of the trait information Ti,a n di s
derived in the Appendix.
There are various ways to code the phenotype of inter-
est and deﬁne the coding function Ti.F o rt h ea n a l y s i so f
aﬀection status, one could specify the coding function to
beTi = 1orTi = 0,dependingonthediseasestatusofthe
proband. However, as we show in the Appendix A, a more
eﬃcient way is to set Ti = 1 − #cases
n for the cases, and
Ti = 0 − #cases
n for the controls. Then the NPBAT statis-
tic is approximately the same as the Cochran-Armitage
Trend test.
If the phenotype Yi is in fact normally distributed and
Ti = Yi − ˆ Yi where ˆ Yi denotes the ﬁtted values of regress-
ing the phenotype Y on any covariates, then the NPBAT
statistic is approximately the same as a t-statistic from a
linear regression. In general, if the phenotype Yi is a con-
tinuous phenotype, we recommend Ti = Yi − μy where
μy is the phenotypic mean in the general population.Lutz etal. BMCGenetics 2013, 14:13 Page 3 of 8
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While it is appealing that the NPBAT statistic is com-
parable to standard methods in these simple scenarios,
the real appeal of the NPBAT statistic is when there is
only phenotype information available for some subjects
but there is genetic information available for all subjects.
For example, in case control studies, an additional quan-
titative phenotype may be available for the cases but not
the controls. When testing for a genetic association with
this additional quantitative phenotype, the NPBAT statis-
tic uses the genotype of both the cases and the controls
with the optimal coded phenotype Ti = Yi − Yoﬀset
where Yoﬀset is a constant. The choice of this constant is
described in detail in the simulations sub-section and the
asymptotic distribution of the NPBAT statistic is derived
in the Appendix. Using this optimal oﬀset choice, the
NPBAT statistic has a substantial increase in power over
other methods such as the NPBAT statistic when an oﬀset
choice of Ti = Yi − ¯ Y or the improved score test, which
is uniformly more powerful than score tests based on the
generalized linear model such as the Cochran-Armitage
trendtest,theallelicχ2 testandthegenotypicχ2 test[21].
Adjustments for population admixture
The NPBAT statistic can be adjusted for population
admixture by using standard methods such as prin-
cipal components analysis or genomic control [22,23].
For example, to account for population admixture, one
can treat the principal components as additional covari-
ate representing population information, and incorporate
them into the test statistic in equation (2) by taking Ti =
Yi − ˆ Yi where ˆ Yi denotes the ﬁtted values of regress-
ing the phenotype Y on the top principal components
that explain the greatest amount of variability in the data.
Note the above approach requires that the phenotype Y is
dichotomous or roughly normally distributed.
Extension to multiple phenotypes
The NPBAT statistic can be extended to m phenotypes to
test the null hypothesis that a marker locus is not linked
to any disease-susceptibility locus for any of m selected
phenotypes. Then the test statistic becomes
S =
n 
i=1
(Xi − Ex)Ti (3)
Note that E(S) = 0 as is the case for the univariate
version above. But here Ti is the m × 1 vector for the m
phenotypes and Xi is just one marker. So S is m × 1. The
m × m variance matrix is the following
VS = ˆ σ2
X
n 
i=1
TiTt
i (4)
where ˆ σ2
X is the variance for marker X based on sample.
Then the NPBAT statistic is the following
χ2
NPBAT = StV−1
S S (5)
Due to the estimation of Ex based on the sample, this
statistic does not have a chi square distribution and a
permutation test needs to be used to assess signiﬁcance
levels, which can be done by using the NPBAT software
package (https://sites.google.com/site/genenpbat/).
Simulations
In genetic association case-control studies, only the cases
mayhaveadditionalphenotypicinformationavailable.For
instance, in a case-control study where the cases have
asthma (the primary phenotype), only the cases may have
FEV measurements (the secondary phenotype). In this
scenario, the secondary phenotype FEV will be more
severe than it would be in the general population and the
analysis of this secondary phenotype can be misleading
due to the ascertainment of subjects based on the primary
phenotype, asthma. To simulate this scenario, we gener-
ated the genotype X for 500 cases and 500 controls and a
secondaryphenotypeYforonlythe500casesfromatrun-
cated normal distribution with standard deviation σ = 1,
mean aX under the alternative and mean 0 under the null
andcutoﬀsuchthatthesecondaryphenotypeinthetop50
percent of the normal distribution. We consider an allele
frequency of p = 20% and a is chosen such that the her-
itability h [24] equals 1%,2%,3%,5%. The solving for a,
a = σ
	
h/2p(1 − p)(1 − h).
WecomputetheNPBATstatisticwiththecodedpheno-
type Ti = Yi−Yoﬀset where Yoﬀset is a constant that ranges
from -5 to 15 and Ex is the sample mean of the genotypes
in the cases. We also compute the NPBAT statistic with
Ex equal to the sample mean of the genotypes in the con-
trols and Ex equal to the sample mean of the genotypes in
thecasesandthecontrols.Wecomparethepowerofthese
three NPBAT statistics to the Improved Score Test, which
is uniformly more powerful than score tests based on the
generalized linear model such as the Cochran-Armitage
trendtest,theallelicχ2 testandthegenotypicχ2 test[21].
We also compare the power of the NPBAT approach to a
standard linear regression.
Under the null hypothesis, the NPBAT method main-
tains a signiﬁcance level of approximately 5% or less as
seen in Figure 1 whether Ex i st h es a m p l em e a no ft h e
cases or the controls or both. Figure 1 also depicts the
power results of these simulations. Note that the spike or
drop in all the plots occurs where Yoﬀset ≈ ¯ Y,t h es a m p l e
mean of the secondary phenotype for the cases since the
secondary phenotype is not available for the controls in
this scenario. The power of the NPBAT approach is max-
imized when Ex is based on the genotype of the controls
and Yoﬀset is signiﬁcantly diﬀerent than the phenotypicLutz etal. BMCGenetics 2013, 14:13 Page 4 of 8
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Figure 1 Power and Signiﬁcance levels for NPBAT, the Improved Score Test and the Likelihood Ratio Test (LRT). This plot compares the
power and type-1 error rate of the NPBAT method using Ex based on the sample mean of the cases, the controls and both the cases and controls.
The power and signiﬁcance levels of this method is compared to the improved score test and a standard linear regression. Note that the spike or
drop in all the plots occurs where Yoﬀset ≈ ¯ Y, the sample mean of the secondary phenotype for the cases since the secondary phenotype is not
available for the controls in this scenario. The power of the NPBAT approach is maximized when Ex is based on the genotype of the controls and
Yoﬀset is signiﬁcantly diﬀerent than the phenotypic mean of the cases. When Ex is based on the genotype of the cases, the power of the NPBAT
approach is similar to the improved score test and the regression. Note that the power of NPBAT approach when Ex is based on the genotype of
both the cases and the controls is best for high values of heritability.Lutz etal. BMCGenetics 2013, 14:13 Page 5 of 8
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mean of the cases. When Ex is based on the genotype of
the cases, the power of the NPBAT approach is similar to
the improved score test and the regression. Note that the
power of NPBAT approach when Ex is based on the geno-
type of both the cases and the controls is best for high
values of heritability.
These simulations show that for case-control studies
when analyzing secondary phenotypes correlated with
case-control status, we recommend to set Yoﬀset to a con-
stant signiﬁcantly diﬀerent from the phenotypic mean of
t h es a m p l ea n dEx equal to the genotypic mean of the con-
trols. In this situation, a robust and eﬃcient choice for
the oﬀset Yoﬀset is the phenotypic mean in the general
population. Note that the results of these simulations are
analogous to the FBAT statistic in family studies where it
was found that when ascertaining cases only from a quan-
titative distribution, one needed to choose an oﬀset that
was outside the range of the case’s phenotypic values [15].
Data analysis
WeappliedtheNPBATmethodtotheGeneticEpidemiol-
ogy of COPD (COPDGene) Study which is a multi-center
case/control study designed to identify genetic factors
associated with COPD and to characterize COPD-related
phenotypes [19]. The study recruited COPD cases and
smoking controls who were non-Hispanic whites and
African Americans ages 45 to 80 with at least 10 pack-
years of smoking history. The study also collected the
Fagerstrom Test for Nicotine Dependence (FTND) to
assess nicotine dependence, but the FTND score was only
available for cases and controls who were current smok-
ers at study enrollment. This data analysis represents the
scenario where the secondary phenotype (FTND score) is
available only in current smokers but the genotypic infor-
mation is available for both current and former smokers.
In the ﬁrst 1,000 Non-Hispanic White (NHW) individ-
uals, the FTND score controlling for age and gender
was tested for an association with SNPs in the CHRNA
3/5 region for COPD cases and controls who are cur-
rent smokers and association was found for rs1051730 or
rs8034191[20].WeappliedtheNPBATstatistictotheﬁrst
1000 NHW using the genotype of both current (307 indi-
viduals) and former smokers (669 individuals), controlling
for age and gender and obtained the results shown in
Table 1 for these 2 SNPs. Note that the NPBAT statistic
performed better than both the Improved Score Test and
the regression controlling for age and gender.
Results and discussion
NPBAT is a new statistical framework for population
based genetic association tests that does not require
making speciﬁc assumptions about the distribution of
the phenotype. By conditioning on the phenotype,
NPBAT is robust against violations of phenotypic model
assumptions. The practical implications of NPBAT are
demonstrated when applied to the COPDGene Study.
FNDS, a measure of nicotine dependence, was assessed in
current smokers that represent 31% of study participants
in COPDGene. We analyzed SNPs shown to be associ-
ated with FNDS [20]. NPBAT identiﬁed the same SNPs as
conventional methods but with slightly greater statistical
signiﬁcance than a linear regression for FNDS control-
ling for age and gender or the improved score test. Other
examples of applications of NPBAT are
1. when a sample is ascertained based on case/control
status and the phenotype of interest is correlated
with case status
2. in a cohort study in which prevalent cases are
excluded (i.e. the classic epidemiologic cohort study)
and the phenotype of interest is correlated with the
disease of interest
3. a pharmacogenetics study using a randomized
clinical trial when participants are ascertained based
on the levels of the target of therapy
The broad application of NPBAT is to scenarios where
samples are ascertained based on selection criteria that
are correlated with the phenotype of interest.
Conclusions
In conclusion, the key advantage that deﬁnes the attrac-
tion of the proposed approach is its robustness against
model speciﬁcation of the phenotypes. This enables
extensions to diﬀerent types of traits and the integration
of complex statistical models for the phenotype. While, at
the same time, the validity of the approach is not com-
promised by such generalization. Though the power is
sensitive to the oﬀset choice, NPBAT is valid regardless
of the oﬀset. As with all population-based association
Table1 Thistabledisplaysthep-valuesfortheassociationbetweentheFagerstromTestforNicotineDependence(FTND)
and the markers listed above for the diﬀerent statistical tests: the NPBAT where Ex = ¯ xc is the genotypic mean of the
current smokers, NPBAT where Ex = ¯ xf is the genotypic mean of the former smokers, the Improved Score Test and a
linear regression
Method NPBAT: Ex = ¯ xc NPBAT: Ex = ¯ xf Improved Score Test Regression
rs1051730 0.00134 0.00138 0.00227 0.00259
rs8034191 0.00386 0.00391 0.00694 0.00744Lutz etal. BMCGenetics 2013, 14:13 Page 6 of 8
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tests, population stratiﬁcation can be a problem. Adjust-
ing for known population sub-structure using principal
components of ancestral informative markers (AIMs) or
using genomic controls can reduce the impact of popu-
lation stratiﬁcation. The NPBAT software package which
implements this method is detailed in the Appendix.
Appendix
Appendix A: Oﬀset choice when Y is binary
The following considers the oﬀset choice for the coded
trait T when Y is binary. Assume the phenotype of interest
is binary and the genotype of interest follows an additive
model. Let r0, r1,a n dr2 denote the number of cases with
0, 1, and 2 disease alleles, respectively. Let R denote the
t o t a ln u m b e ro fc a s e s .L e tS denote the total number of
controls. Let n0, n1,a n dn2 denote the number of cases
and controls with 0, 1, and 2 disease alleles, respectively.
Let N = S + R denote the total number of cases and
controls. In this scenario, the standard statistical method
used is the Cochran-Armitage Trend test which can be
written as follows:
zCochran =
N (r1 + 2r2) − R(n1 + 2n2)

SR
N

N (n1 + 4n2) − (n1 + 2n2)2 (6)
In this scenario, let the coded phenotype Ti = Yi −
μy where μy is the oﬀset. The NPBAT statistic has the
following form:
N (r1 + 2r2) − R(n1 + 2n2)

Nμ2
y
R

+

N(1−μy)
2
S

SR(N(n1+4n2)−(n1+2n2)2)
N−1

(7)
Note that the numerators of both statistics are the same.
The ratio of the test statistics can be written as follows:
StatCochran
StatNPBAT
=

N
N − 1

1 +
1
γ

μ2
y + (1 + γ)(1 − μy)2
(8)
where γ = #cases
#controls. Given this ratio, the power of the
NPBAT statistic relative to the Cochran-Armitage trend
test is maximized for the oﬀset choice μ
optimal
y =
γ
1+γ =
#cases
N . For example, if the ratio of the cases versus the con-
trols is 1, the oﬀset choice μy is 1
2. This corresponds to
equallyweightingthecasesandcontrolsintheconditional
teststatistic.ForlargesamplesizeN,suchthat


N
N−1 ≈ 1,
the ratio of the test statistics is approximately one when
the oﬀset is set to μ
optimal
y = #cases
n . Consequently, for the
optimal oﬀset choice, the test statistics are approximately
the same.
Appendix B: asymptotic distribution when the secondary
phenotype is available for both the cases and controls
ToderivetheasymptoticdistributionoftheNPBATstatis-
tics for various phenotypic oﬀset choices, let σ2
X denote
t h ev a r i a n c eo fXa n dσ2
Y denote the variance of Y. Let
||a|| denote the Euclidean norm. Let Toﬀset = ((Y1 −
Yoﬀset)...(Yn − Yoﬀset))t and let Tμ = (Tμ1,...,Tμn)t =
((Y1 − ¯ Y)...(Yn − ¯ Y))t where Tμi = (Yi − ¯ Y).L e tXt =
(X1 − ¯ X,...,Xn − ¯ X).D e ﬁ n eZi =
(Xi−¯ X)Tμi
||Tμ|| ˆ σx .T h e n
n 
i=1
Zi =
XtTμ
||Tμ|| ˆ σx. By treating X as random given Y is ﬁxed, it can
be shown that the Zis are independent, E(Zi) = 0a n d
Var
 n 
i=1
Zi

= 1. The Lindberg condition [25] for Zi,
which ensures asymptotic normality of

Zi,ist h e ngi v e n
by
∀ >0:limn→∞
 n 
i=1

|Zi|≥ 
Z2
i dP

= 0( 9 )
Since Zi has a discrete distribution, the Lindberg condi-
tion can only be fulﬁlled when the integration set {|Zi|≥
 } is empty for n →∞ . Since X is the coded genotype
and Y is a biological quantity, assume ˆ σx  = 0, ˆ σy  = 0a n d
both are ﬁnite. Then, there exists some constant K such
that |(Xi−¯ X)|
 Tμi
 
ˆ σx ˆ σy ≤ K. Hence we rewrite the Lindberg
condition by
∀ >0:  ≤ |Zi| =

(Xi − ¯ X)



Tμi


ˆ σx||Tμ||
≤
K
n
→ 0a sn →∞
(10)
Hence the integral in the Lindberg condition is always
computed over a set that is empty for n →∞ .T h u st h e
Lindberg condition is always fulﬁlled when the regularity
condition holds. Then the Lindberg theorem [26] implies
convergence to normality. Then

||T||
||Tμ||

StatNPBAT =
n 
i=1
Zi →d N (0,1) (11)
Note that the statistic is maximized and has a standard
normal distribution when Yoﬀset = E[Y].
Appendix C: asymptotic distribution when the secondary
phenotype is only available for the cases
Here, we derive the asymptotic distribution of the NPBAT
statistic for secondary phenotypes in case/control studies.
Consider a case control study where genetic information
is available for both the cases and the controls, but the
phenotypic information is only available for the cases.
Here n is only the number of cases and all summations
are only over the number of cases since the phenotypic
information is not available for the controls where as in
Appendix B, n is the number of cases and controls andLutz etal. BMCGenetics 2013, 14:13 Page 7 of 8
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the summation is over both the number of cases and con-
trols. Let ¯ Xcases denote the sample mean of the genotypes
of the cases and σ2
X b et h et r u ev a r i a n c eo ft h eg e n o t y p e s .
Let Ex = ¯ Xcontrols b et h es a m p l em e a no ft h eg e n o t y p e s
of the controls. Under the null hypothesis and assuming
no population stratiﬁcation, the sample mean of the geno-
types of the cases and the sample mean of the genotypes
of the controls both converge to E[X]s i n c eXi sn o ta s s o -
ciated with Y. Let Xtext = (X1 − ¯ Xtext...Xn − ¯ Xtext)t where
text=cases or controls, meaning X1..Xn is the coded geno-
type of the cases but ¯ X can be computed based on the
cases, the controls, or both. Deﬁne
Zi =

Xi − ¯ Xcontrol

(Yi − Yoﬀset)
ˆ σx


||Tμ||2 + 2(¯ Y − Yoﬀset)2
(12)
then
n 
i=1
Zi =
Xt
controlT
ˆ σx


||Tμ||2 + 2(¯ Y − Yoﬀset)2
=
Xt
caseTμ + n(¯ Xcase − ¯ Xcontrol)(¯ Y − Yoﬀset)
ˆ σx


||Tμ||2 + 2(¯ Y − Yoﬀset)2
(13)
It is important to note that the Zis are independent,
E(Zi) = 0a n dVar
 n 
i=1
Zi

= 1, which is obtained
by ﬁrst taking the conditional expectation treating X as
random and Y as ﬁxed. The Lindberg condition [25] for
Zi, which ensures asymptotic normality of

Zi,i st h e n
given by
∀ >0:limn→∞
 n 
i=1

|Zi|≥ 
Z2
i dP

= 0 (14)
Since Zi has a discrete distribution, the Lindberg condi-
tion can only be fulﬁlled when the integration set {|Zi|≥
 } is empty for n →∞ . Since X is the coded genotype
and Y is a biological quantity, assume ˆ σx  = 0, ˆ σy  = 0a n d
both are ﬁnite. Then, there exists some constant K such
that |(Xi−¯ Xcontrol)||Ti|
ˆ σx ˆ σy ≤ K. Hence we rewrite the Lindberg
condition by
∀ >0:  ≤ |Zi| =

(Xi − ¯ Xcontrol)

|Ti|
ˆ σx


||Tμ||2 + 2(¯ Y − Yoﬀset)2
≤

(Xi − ¯ Xcontrol)

|Ti|
ˆ σx||Tμ||
≤
K
n
→ 0asn →∞
(15)
Hence the integral in the Lindberg condition is always
computed over a set that is empty for n →∞ .T h u st h e
Lindberg condition is always fulﬁlled when the regularity
condition holds. Then the Lindberg theorem [26] implies
convergence to normality. Then
||T||


||Tμ||2 + 2(¯ Y − Yoﬀset)2
StatNPBAT =
n 
i=1
Zi →d N(0,1)
(16)
Then the NPBAT statistic is normally distributed with
mean zero and variance given above. Note that the vari-
ance is always greater than or equal to one and equals one
when Yoﬀset = E[Y] . Note that if Yoﬀset = ¯ Y and Ex =
¯ Xcontrols then NPBAT has a standard normal distribution.
As seen in the Simulations section and Figure 1, when
EX is based on the the controls and the phenotype infor-
mation is only available for the cases, then the power is
maximized when Yoﬀset  = ¯ Y because the variance equals
the minimum when Yoﬀset ≈ E[Y].
Appendix D: NPBAT software
A software package implemented in C++ to compute both
single phenotype and multiple phenotypes NPBAT statis-
tics is available for download at the following website:
https://sites.google.com/site/genenpbat/. In addition to
NPBAT statistics, other population based statistics such
as the Armitage Trend Test, Fisher Exact Test are also
available. Currently, only two platforms are supported:
linux64 and windows64. The NPBAT software package
reads in genetic data through the PLINK style pedigree
(ped), map (map) and phenotype (phe) ﬁles. The website
provides detail information on how to use the software
package.
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